Daily non-political popular news in brief.
GSK's Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
06-02-2007 · EurekAlert!GlaxoSmithKline (GSK) today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer. These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.
Read more »
Keywords: gsk, pazopanib, shows, positive, results, patients, advanced, rcc, ovarian, cancer, show, result, patient
« Previous | Next »
Similar news on "GSK's Pazopanib shows positive results in patients with advanced RCC and ovarian cancer":
- GSK's Pazopanib shows positive results in patients with advanced renal cell carcinoma
06-02-2007 · EurekAlert!
GlaxoSmithKline (GSK) today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) . These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.
Similar news · Read more »
- VEGF Trap shows activity in patients with advanced ovarian cancer
06-02-2007 · EurekAlert!
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings, which are being presented today at the American Society of Clinical Oncology’s annual meeting, may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.
Similar news · Read more »
- What's going on in the body? Advanced time-of-flight PET takes a superior 'look'
06-04-2007 · EurekAlert!
Moving from computer simulation to patient images, researchers are now demonstrating the benefits that time-of-flight/PET imaging can provide for cancer patients. The result? Superior images and shorter patient scan times for starters, according to a study released at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals, June 2-6 in Washington, D.C.
Similar news · Read more »
- Drug shows activity against brain metastases
06-03-2007 · EurekAlert!
The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial being presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.
Similar news · Read more »
- Cryoablation continues to show good results for kidney cancer patients
11-25-2007 · EurekAlert!
A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure.
Similar news · Read more »
- Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
09-28-2007 · EurekAlert!
An oral presentation covering interim results from a U.K. Phase Ia/Ib combination Reolysin and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute conference on Oct. 2, 2007.
Similar news · Read more »
- Novel MS drug shows promise in 2 lethal leukemias
08-28-2007 · EurekAlert!
A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.
Similar news · Read more »
- OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
06-02-2007 · EurekAlert!
The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).
Similar news · Read more »
- Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia
12-09-2007 · EurekAlert!
Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at the University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
- Early Phase II results show bosutinib safe, effective for CML
12-11-2007 · EurekAlert!
A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at the University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
